James B. Leverenz

发表

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain

C. Kawas, M. Hill, E. Head, 2007, Neurobiology of Aging.

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

B. Gerton, G. Watson, P. Green, 2012, Archives of neurology.

Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele

G. Schellenberg, S. Craft, R. Roth, 2003 .

Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

T. Montine, N. Postupna, Jing Zhang, 2013, JAMA neurology.

A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology.

G. Schellenberg, T. Montine, V. Lee, 2007, Brain : a journal of neurology.

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.

K. Kovacina, P. McMillan, J. Kulstad, 2003, The American journal of pathology.

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK, GRB14, and KIAA0825 as novel risk loci for Alzheimer disease: the Alzheimer Disease Genetics Consortium

Pavel P. Kuksa, Nicholas R. Wheeler, Timothy J. Hohman, 2023, medRxiv.

Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.

G. Schellenberg, M. Pandian, D. Nochlin, 1997, Alzheimer disease and associated disorders.

Whole genome‐wide sequence analysis of long‐lived families (Long‐Life Family Study) identifies MTUS2 gene associated with late‐onset Alzheimer's disease

A. Yashin, H. Hakonarson, M. Cuccaro, 2024, Alzheimer's & Dementia.